SCHEMBL6071833

SCHEMBL6071833

N#Cc1c(N)nc2ccccc2c1Cn1ccnn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 7/20 0.46
ALDH1A1 P00352 5/20 0.45
KDM4E B2RXH2 5/20 0.45
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
HTT P42858 2/20 0.37
EGFR P00533 1/20 0.36
HSD17B10 Q99714 3/20 0.36
LMNA P02545 2/20 0.36
GLA P06280 2/20 0.36
HPGD P15428 2/20 0.36
CASP1 P29466 2/20 0.36
CASP7 P55210 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
GAA P10253 2/20 0.36
TP53 P04637 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7842318 0.82 MEN1 (0.47) CYP19A1ALDH1A1KDM4EKMT2AMEN1
SCHEMBL6071828 0.81 CYP19A1 (0.44) CYP19A1ALDH1A1KDM4EKMT2ANPSR1
SCHEMBL6072069 0.74 KDM4E (0.50) ALDH1A1KDM4EKMT2AMEN1NPSR1
SCHEMBL6071945 0.73 ALDH1A1 (0.49) ALDH1A1KDM4EKMT2AMEN1NPSR1
SCHEMBL7842311 0.73 KDM1A (0.46) CYP19A1ALDH1A1KDM4EKMT2AMEN1
SCHEMBL6071926 0.71 ALDH1A1 (0.46) ALDH1A1KDM4EKMT2AMEN1NPSR1
SCHEMBL6265005 0.70 TLR8 (0.64) ALDH1A1KDM4ENPSR1HSD17B10GLA
SCHEMBL6252164 0.70 KDM4E (0.60) ALDH1A1KDM4EKMT2AHTTHSD17B10
SCHEMBL6071923 0.69 ALDH1A1 (0.44) ALDH1A1KDM4EKMT2AMEN1NPSR1
SCHEMBL6253855 0.68 KDM4E (0.56) ALDH1A1KDM4EKMT2AMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060264460-A1 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same WYETH (US) 2006-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264460-A1 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same TNNI3K, CSNK1A1L, CDKL1 CYP19A1 2539/4885ALDH1A1 3975/4885KDM4E 1032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.